NasdaqGS - Nasdaq Real Time Price USD

Pacira BioSciences, Inc. (PCRX)

26.75

+0.60

+(2.29%)

At close: 4:00:00 PM EDT

26.75

0.00

(0.00%)

After hours: 4:10:43 PM EDT

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISBANE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new preliminary data which suggest

GlobeNewswire 5 days ago

PCRX
+2.29%
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21st at 8:30AM ET.2025 Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:45AM

GlobeNewswire 6 days ago

PCRX
+2.29%
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.

Zacks 11 days ago

PCRX
+2.29%
Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ...

Pacira BioSciences Inc (PCRX) reports robust Q1 performance with increased EXPAREL sales, strategic acquisitions, and a $300 million stock repurchase program.

GuruFocus.com 11 days ago

PCRX
+2.29%
Pacira: Q1 Earnings Snapshot

The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 57 cents per share. The specialty drugmaker posted revenue of $168.9 million in the period, which missed Street forecasts.

Associated Press Finance 12 days ago

PCRX
+2.29%
Pacira BioSciences Reports First Quarter 2025 Financial Results

-- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°

GlobeNewswire 12 days ago

PCRX
+2.29%
Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

-- Data will be featured at EULAR Annual Congress – BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201 (enekinragene inzadenovec). The data is being presented at the 2025 European Alliance of Associations for Rheumatology (EULAR) Annual Cong

GlobeNewswire 14 days ago

PCRX
+2.29%
Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

Data will be featured at the ASGCT 28th Annual MeetingBRISBANE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at

GlobeNewswire 18 days ago

PCRX
+2.29%
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

BRISBANE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter financial results after the close of the U.S. markets on Thursday May 8, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question

GlobeNewswire 21 days ago

PCRX
+2.29%
Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

-- PCRX-201 demonstrated two years of clinically meaningful improvements in pain, stiffness and function across all structural severity subgroups, including advanced disease -- -- Study Findings Presented at 2025 OARSI World Congress-- BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced new data demonstrating its loca

GlobeNewswire 22 days ago

PCRX
+2.29%
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

-- Poster to be presented at OARSI World Congress on Osteoarthritis -- BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the upcoming presentation of new 104-week data in support of its locally administered gene therapy candidate, PCRX-201 (enekinragene inzadenovec). The data is being presented at the 2025 Osteoarth

GlobeNewswire 28 days ago

PCRX
+2.29%
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira" or the "Company").

PR Newswire 29 days ago

PCRX
+2.29%
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

-- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan – -- Continued focus on margin expansion and operational efficiency -- BRISBANE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reaffirmed its commitment to enhancing shareholder value by outlining a series of strategic actions designed

GlobeNewswire last month

PCRX
+2.29%
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Pacira BioSciences, Inc. (NASDAQ:PCRX) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American […]

Insider Monkey last month

PCRX
+2.29%
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved

GlobeNewswire last month

PCRX
+2.29%
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

Zacks last month

PCRX
+2.29%

SRPT

EWTX
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.

Zacks last month

EWTX

PCRX
+2.29%

SRPT
Pacira price target raised to $28 from $25 at Truist

Truist analyst Les Sulewski raised the firm’s price target on Pacira (PCRX) to $28 from $25 and keeps a Hold rating on the shares. The firm cites a settlement with eVenus and counterparts for their generic entry of bupivacaine liposome injectable suspension – gExparel – and now envision peak Exparel sales of $740M by 2029, the analyst tells investors in a research note. The deal also removes the much debated overhang, Truist adds. Published first on TheFly – the ultimate source for real-time, ma

TipRanks last month

PCRX
+2.29%
PCRX Stock Soars on Exparel Patent Settlement With Generic Players

Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.

Zacks last month

FRE.DE

PCRX
+2.29%
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations beginning in 2039 -- BRISBANE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to

GlobeNewswire last month

PCRX
+2.29%

Performance Overview

Return	PCRX	S&P 500 (^GSPC)
YTD	+41.99%	+1.00%
1-Year	-12.61%	+11.91%
3-Year	-57.93%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ...

Pacira: Q1 Earnings Snapshot

Pacira BioSciences Reports First Quarter 2025 Financial Results

Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis

Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis

Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee

Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders

Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Pacira price target raised to $28 from $25 at Truist

PCRX Stock Soars on Exparel Patent Settlement With Generic Players

Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

Performance Overview